Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inflammation01:38

Inflammation

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Allergic Reactions02:06

Allergic Reactions

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melittin in AllergoOncology: From Honey Bee Venom to Anti-Cancer Therapeutic Innovation-An EAACI Position Paper.

Allergy·2026
Same author

Meaningful outcomes in food allergy immunotherapy: Measuring what counts.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Mast Cells in Acute COVID-19 Patients.

Allergy·2026
Same author

CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models.

International archives of allergy and immunology·2026
Same author

New advances in our understanding of itch.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Epithelial-Immune Cell Crosstalk in Salivary Gland Tumors: Implications for Tumor Progression and Diagnostic Assessment.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 19, 2026

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Are we ready to downregulate mast cells?

Laila Karra1, Beata Berent-Maoz, Micha Ben-Zimra

  • 1Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Jerusalem 91120, Israel.

Current Opinion in Immunology
|October 20, 2009
PubMed
Summary
This summary is machine-generated.

Targeting mast cells (MCs) via TRAIL and inhibitory receptors CD300a and Siglec-8 offers a new approach to treat allergic inflammation and related diseases by downregulating MC function and survival.

More Related Videos

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Related Experiment Videos

Last Updated: Jun 19, 2026

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
11:31

Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays

Published on: July 4, 2018

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
09:07

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice

Published on: May 27, 2015

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Mast cells (MCs) play a crucial role in allergic inflammation (AI) and related disorders.
  • Downregulating MC function and survival is a therapeutic goal for MC-associated diseases.

Purpose of the Study:

  • To investigate the potential of targeting specific receptors on human MCs (hMCs) for therapeutic intervention.
  • To explore the roles of TRAIL, CD300a, and Siglec-8 in modulating hMC activity.

Main Methods:

  • Analysis of human MC expression of death receptor (DR) TRAIL and inhibitory receptors (IRs) CD300a and Siglec-8.
  • Investigation of TRAIL function regulation by IgE-dependent MC activation.
  • Assessment of CD300a and Siglec-8 effects on hMC activation and survival in vitro and IgE-mediated responses in vivo.

Main Results:

  • Human MCs express functional DR TRAIL, whose activity is enhanced by IgE-dependent activation.
  • Newly identified IRs, CD300a and Siglec-8, effectively reduce hMC activation and survival.
  • These IRs demonstrate potent inhibition of IgE-mediated responses in vivo.

Conclusions:

  • Selective targeting of TRAIL and IRs (CD300a, Siglec-8) on MCs presents a novel immunopharmacological strategy.
  • This approach holds promise for downregulating MC-associated inflammatory diseases.